These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 20808308)
1. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Baba Y; Nosho K; Shima K; Meyerhardt JA; Chan AT; Engelman JA; Cantley LC; Loda M; Giovannucci E; Fuchs CS; Ogino S Br J Cancer; 2010 Sep; 103(7):1025-33. PubMed ID: 20808308 [TBL] [Abstract][Full Text] [Related]
2. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Morikawa T; Kuchiba A; Liao X; Imamura Y; Yamauchi M; Qian ZR; Nishihara R; Sato K; Meyerhardt JA; Fuchs CS; Ogino S Int J Cancer; 2012 Sep; 131(5):1169-78. PubMed ID: 22038927 [TBL] [Abstract][Full Text] [Related]
3. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197 [TBL] [Abstract][Full Text] [Related]
4. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Baba Y; Nosho K; Shima K; Hayashi M; Meyerhardt JA; Chan AT; Giovannucci E; Fuchs CS; Ogino S Cancer; 2011 Apr; 117(7):1399-408. PubMed ID: 21425139 [TBL] [Abstract][Full Text] [Related]
5. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Li T; Liao X; Lochhead P; Morikawa T; Yamauchi M; Nishihara R; Inamura K; Kim SA; Mima K; Sukawa Y; Kuchiba A; Imamura Y; Baba Y; Shima K; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S; Qian ZR Ann Surg Oncol; 2014 Dec; 21(13):4164-73. PubMed ID: 25023548 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368 [TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368 [TBL] [Abstract][Full Text] [Related]
8. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717 [TBL] [Abstract][Full Text] [Related]
9. Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Kim JG; Lee SJ; Chae YS; Kang BW; Lee YJ; Oh SY; Kim MC; Kim KH; Kim SJ Oncology; 2013; 85(2):78-85. PubMed ID: 23860205 [TBL] [Abstract][Full Text] [Related]
10. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Kim SA; Inamura K; Yamauchi M; Nishihara R; Mima K; Sukawa Y; Li T; Yasunari M; Morikawa T; Fitzgerald KC; Fuchs CS; Wu K; Chan AT; Zhang X; Ogino S; Qian ZR Br J Cancer; 2016 Jan; 114(2):199-206. PubMed ID: 26742007 [TBL] [Abstract][Full Text] [Related]
11. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721 [TBL] [Abstract][Full Text] [Related]
12. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660 [TBL] [Abstract][Full Text] [Related]
13. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150 [TBL] [Abstract][Full Text] [Related]
17. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056 [TBL] [Abstract][Full Text] [Related]
20. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. Morikawa T; Kuchiba A; Yamauchi M; Meyerhardt JA; Shima K; Nosho K; Chan AT; Giovannucci E; Fuchs CS; Ogino S JAMA; 2011 Apr; 305(16):1685-94. PubMed ID: 21521850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]